Inotiv, Inc. Expands Pathology Services to Include Medical Device Pathology, Hires Nicolette Jackson to Lead Effort


Nicolette Jackson, DMV, MS, DACVP

Dr. Nicolette Jackson joins Inotiv as Director, Medical Device Pathology

Dr. Nicolette Jackson joins Inotiv as Director, Medical Device Pathology

WEST LAFAYETTE, Ind., June 28, 2021 (GLOBE NEWSWIRE) – Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in non-clinical and analytical drug discovery and development services, today announced the expansion of the Company’s pathology services to include medical device pathology. Nicolette Jackson, DVM, MS, DACVP, has joined the company as Director, Medical Device Pathology, to lead this effort.

The company began supporting medical device customers with the 2019 acquisition of Preclinical Research Services, Inc. in Fort Collins, Colorado. The Fort Collins site has brought in-depth expertise in surgical and pharmacological models to support the medical device industry.

Inotiv has a strong team of board-certified clinical and anatomical veterinary pathologists who have focused on supporting pharmaceutical research and development. However, the histology and pathology services supporting the Company’s medical device customers have often been contracted out to third parties.

“I am pleased to report that we are now able to provide broader and more comprehensive in-house services to our medical device customers,” said Dr. Don Maul, the company’s senior vice president, Surgical Models. “We believe that Dr. Jackson’s experience and expertise will allow us to significantly reduce our reliance on external contractors for medical device pathology.

Dr. Stewart Jacobson, Senior Vice President of Pathology at Inotiv, added, “I am delighted that Dr. Jackson is joining Inotiv. His skills and expertise in medical device pathology are widely recognized in our industry, making him an important strategic addition to our pathology team.

“I am delighted to join a company with such a broad service offering and an exceptional reputation,” said Dr. Jackson. “I have worked with the Fort Collins site team for many years and look forward to supporting Inotiv’s medical device customers full time. “

Dr. Jackson is a graduate of the American College of Veterinary Pathologists. She holds a DVM from Kansas State University, an MSc in Biomedical Sciences from Texas A&M, and a BSc in Biological and Agricultural Engineering from Kansas State. Dr Jackson is Chair of the Medical Devices Scientific Interest Group and a member of the Society of Toxicologic Pathology Medical Device Implantation Site Assessment Working Group.

About the company
Inotiv, Inc. is a leading contract research organization specializing in non-clinical and analytical drug discovery and development services. The Company is focused on developing innovative services supporting its clients’ discovery and development goals for better decision making and faster goal achievement. The Company’s products focus on increasing efficiency, improving data and reducing the cost of bringing new drugs to market. Visit inotivco.com for more information about the Company.

This press release may contain forward-looking statements subject to risks and uncertainties, including, but not limited to, risks and uncertainties relating to changes in the market and demand for our products and services, development, marketing and sales of products and services, changes in technology, industry and regulatory standards, timing of acquisitions and the successful closing, integration and commercial and financial impact thereof, impact of the COVID-19 pandemic on the economy, demand for our services and products and operations, including the actions taken by government authorities to address the pandemic, which may precipitate or exacerbate other risks and / or uncertainties, expansion and related efforts, and various other market and operational risks, including those detailed in the documents filed by the Company with Securities and Excha nge Commission of the United States.

Company contact

Investor Relations

Inotiv, Inc.

The Equity Group Inc.

Beth A. Taylor, Chief Financial Officer

Kalle Ahl, CFA

(765) 497-8381

(212) 836-9614

[email protected]

[email protected]

Devin Sullivan

(212) 836-9608

[email protected]

A photo accompanying this announcement is available on https://www.globenewswire.com/NewsRoom/AttachmentNg/b89620a3-7b94-48fc-bb84-78ae78fcef53


About Hector Hedgepeth

Check Also

Silence Therapeutics Announces First Quarter 2022 Results

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, …

Leave a Reply

Your email address will not be published.